CELLA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.374
EU - Europa 515
AS - Asia 269
OC - Oceania 2
Totale 4.160
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.370
CN - Cina 162
SE - Svezia 112
FI - Finlandia 96
DE - Germania 87
SG - Singapore 87
UA - Ucraina 69
FR - Francia 61
GB - Regno Unito 35
IT - Italia 29
VN - Vietnam 12
IE - Irlanda 10
NL - Olanda 8
CA - Canada 4
IN - India 4
ES - Italia 2
HK - Hong Kong 2
HR - Croazia 2
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
CZ - Repubblica Ceca 1
GR - Grecia 1
NZ - Nuova Zelanda 1
RO - Romania 1
TR - Turchia 1
Totale 4.160
Salva come PNG Salva come JPEG
Città #
Fairfield 475
Jacksonville 353
Woodbridge 316
Chandler 279
Ann Arbor 250
Houston 243
Wilmington 235
Ashburn 231
Seattle 185
Cambridge 174
Princeton 126
San Diego 64
Singapore 58
Roxbury 45
Beijing 42
Nanjing 37
Helsinki 30
Boardman 25
Medford 23
Shenyang 18
Padova 17
Des Moines 15
Santa Clara 15
Norwalk 13
Changsha 12
Dong Ket 12
Nanchang 12
Hebei 11
Dublin 10
Guangzhou 9
Jiaxing 9
Redwood City 8
New York 7
London 6
Borås 5
Chicago 5
Ogden 3
Washington 3
Aachen 2
Dallas 2
Detroit 2
Dugi Rat 2
Jinan 2
Kharkiv 2
Kilburn 2
Lanzhou 2
Nürnberg 2
Abbeville 1
Acton 1
Auburn Hills 1
Baku 1
Brno 1
Brussels 1
Calgary 1
Central 1
Chiswick 1
Costa Mesa 1
Coux 1
Edinburgh 1
Falls Church 1
Frankfurt am Main 1
Fremont 1
Geislingen an der Steige 1
Groningen 1
Hamilton 1
Hefei 1
Hounslow 1
Indiana 1
Islington 1
Liverpool 1
Los Angeles 1
Madrid 1
Margherita Di Savoia 1
Marseille 1
Melbourne 1
Montreal 1
Palermo 1
Pune 1
San Jose 1
Shanghai 1
Southwark 1
Taizhou 1
Tianjin 1
Toronto 1
Verona 1
Yenibosna 1
Totale 3.438
Salva come PNG Salva come JPEG
Nome #
Blood oxidative status and selectins plasma levels in healthy donors receiving granulocyte-colony stimulating factor 137
Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. 122
Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: The missing piece in the puzzle of their increased cardiovascular risk? 117
Aspirin and bleeding time 111
Coagulation Activation in Children with Sickle Cell Disease Is Associated with Cerebral Small Vessel Vasculopathy 107
Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center 106
Heparin induced thrombocytopenia: Prevalence in a large cohort of patients and confirmed role of PF4/heparin complex as the main antigen for antibodies 105
von Willebrand factor abnormalities in aortic valve stenosis:pathophysiology and impact on bleeding. 102
Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration 96
Defining the thrombotic risk in patients with myeloproliferative neoplasms. 95
Markers of endothelial function in pediatric stem cell transplantation for acute leukemia 85
Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP) 85
Biochemical markers of endothelial activation in primary hyperparathyroidism 83
Lack of inhibitors in coumarin plasma. 81
Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms 81
Effect of Bosentan on Plasma Markers of Endothelial Cell Activity in Patients with Secondary Pulmonary Hypertension Related to Connective Tissue Diseases. 80
ETUDE DE CHOLANGIOCHOLECYSTOGRAPHIE ENDOVEINEUSE AVEC UN SEL DE MEGLUMINE DE L'ACIDE IODOSSAMMIQUE AVEC RECHERCHE SUR LA FIBRINOLYSE. 78
Uneventful coronary artery bypass surgery without prophylatic replacement therapy in a patient with a novel heterozygous FVII gene deletion 78
Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease 77
Endothelial dysfunction in cardiac allograft vasculopathy. Potential pharmacological interventions. 77
In vivo platelet release reaction in patients with heart valve prosthesis. 75
Soluble thrombomodulin as predictor of incident coronary heart disease 74
Hyperthyroidism as a cause of pulmonary arterial hypertension. A prospective study 73
Revascularization for acute coronary occlusion in young woman following radiation 73
Plasma markers of endothelial dysfunction in pulmonary hypertension 71
Disappearance of human platelet factor 4 (PF4) in rabbits: does an immediate component exist? 70
Endothelial dysfunction in haemophilia patients. 67
Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. 67
Heparin-induced thrombocytopenia. 65
Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticules. 64
Contribution of fibrinolytic tests to the differential diagnosis of veno-occlusive disease complicating pediatrica hematopoietic stemm cell transplantation 64
-Sustained response to anti-CD20 monoclonal antibody in severe acute primary immune thrombocytopenic purpura. Report of one adult case 64
Beta-thromboglobulin (beta tg) and platelet factor 4 (PF4) in patients with myeloproliferative diseases. 64
Endothelial cell activity in chronic obstructive pulmonary disease without severe pulmonary hypertension 63
Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. 61
Functional heterogenity of anti-heparin-platelet factor 4 antibodies: Implications in the pathogenesis of HIT syndrome. 58
Tissue factor pathway inhibitor levels in patients with homocystinuria 58
Clearance and in vivo release by heparin of human platelet factor 4 (PF4) in the rabbit. 57
Human platelet factor 4 (PF 4) disappearance in rabbits fed an atherogenic diet. 56
Value of thrombin-antithombin III complex in major orthopedic surgery: relation to thr onset of venous thromboembolism 55
Heparin-induced thrombocytopenia - prevalence in 236 patients and evidence that complex pf4 - heparin is the main antigen for the antibodies 54
Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis. 54
[Use and misuse of hospital admission in a department of medicine in Padua]. 52
The effect of increasing heparin doses and of heparinoid on platelet factor 4 (PF4) release in normal subjects. 52
Role of PAI-1 in the differential diagnosis of hepatic veno-occlusive disease complicating hematopoietic stem cell transplantation: study in a pediatric population 51
Heparins and release. 50
Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica 2002; 87: 1180-1184 3,216 49
Endothelial Activation Markers Soluble E-Selectin and von Willebrand Factor in Primary Hyperparathyroidism 48
Possible role of platelet factor 4 (PF4) in modulating heparin-induced aldosterone suppression. 46
Idiopathic thrombocytopenic purpura treated with steroid therapy does not prevent acute myocardial infarction 46
Exogenous heparin reduces soluble plasma thrombospondin levels 44
Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population 44
Heparin induced thrombocytopenia: State of the art 42
Evidence for the need of long-term antithrombotic therapy in patients with porcine heterograft heart valve. 37
Effect of recombinant-tissue plasminogen activator, low molecular weight urokinase and unfractionated heparin on platelet aggregation. 37
The trombin-antithrombin complex in rheumatoid arthritis 34
Platelet-specific proteins in patients with transient ischemic attacks. (Effects of anti-platelet drugs). 33
Effect of cellulose acetate 0.2 micron filter on platelet specific proteins plasma levels. 33
Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor patway inhibitor plasma antigen level in chronic dyalisis. 31
Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders 28
Increased endothelial and platelet soluble selectins in heparin-induced thrombocytopenia associated with thrombosis 28
Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular weigh heparin and with a direct thrombin inhibitor 26
Soluble plasma thrmbomodulin levels in patients with myeloproloferative disorder. 25
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications-a review 23
Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukemia with trisomy 8, trisomy 21 and coutaneous involvment 19
Preclinical differentioation of low molecular weight heparins 14
Totale 4.202
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.857
article - articoli 13.615
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 102
patent - brevetti 0
selected - selezionate 0
volume - volumi 140
Totale 27.714
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020761 0 0 17 63 85 78 72 107 114 111 59 55
2020/2021624 37 55 28 52 18 69 14 74 110 52 69 46
2021/2022761 4 92 50 85 33 73 18 100 46 6 90 164
2022/2023563 144 55 22 60 96 70 0 24 55 0 28 9
2023/2024222 8 28 34 21 20 24 7 3 5 1 42 29
2024/2025113 0 51 62 0 0 0 0 0 0 0 0 0
Totale 4.202